nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludrocortisone—AR—scrotum—muscle cancer	0.223	0.415	CbGeAlD
Fludrocortisone—Muscle atrophy—Vincristine—muscle cancer	0.0344	0.0835	CcSEcCtD
Fludrocortisone—Aseptic necrosis—Methotrexate—muscle cancer	0.0342	0.0828	CcSEcCtD
Fludrocortisone—NR3C2—smooth muscle tissue—muscle cancer	0.023	0.0427	CbGeAlD
Fludrocortisone—NR3C2—renal system—muscle cancer	0.0221	0.0411	CbGeAlD
Fludrocortisone—NR3C2—cardiac atrium—muscle cancer	0.0198	0.0369	CbGeAlD
Fludrocortisone—NR3C2—tendon—muscle cancer	0.0173	0.0321	CbGeAlD
Fludrocortisone—AR—smooth muscle tissue—muscle cancer	0.017	0.0317	CbGeAlD
Fludrocortisone—AR—renal system—muscle cancer	0.0164	0.0305	CbGeAlD
Fludrocortisone—NR3C2—vagina—muscle cancer	0.016	0.0298	CbGeAlD
Fludrocortisone—NR3C1—embryo—muscle cancer	0.0157	0.0292	CbGeAlD
Fludrocortisone—NR3C2—head—muscle cancer	0.0148	0.0275	CbGeAlD
Fludrocortisone—AR—cardiac atrium—muscle cancer	0.0147	0.0273	CbGeAlD
Fludrocortisone—NR3C2—testis—muscle cancer	0.0143	0.0266	CbGeAlD
Fludrocortisone—AR—tendon—muscle cancer	0.0128	0.0238	CbGeAlD
Fludrocortisone—NR3C1—smooth muscle tissue—muscle cancer	0.0123	0.0229	CbGeAlD
Fludrocortisone—AR—vagina—muscle cancer	0.0119	0.0221	CbGeAlD
Fludrocortisone—NR3C1—renal system—muscle cancer	0.0119	0.0221	CbGeAlD
Fludrocortisone—Diabetic—Methotrexate—muscle cancer	0.0118	0.0286	CcSEcCtD
Fludrocortisone—AR—head—muscle cancer	0.011	0.0204	CbGeAlD
Fludrocortisone—Optic neuritis—Etoposide—muscle cancer	0.0107	0.0259	CcSEcCtD
Fludrocortisone—NR3C1—cardiac atrium—muscle cancer	0.0106	0.0198	CbGeAlD
Fludrocortisone—AR—testis—muscle cancer	0.0106	0.0197	CbGeAlD
Fludrocortisone—Osteonecrosis—Methotrexate—muscle cancer	0.0106	0.0256	CcSEcCtD
Fludrocortisone—Cardiomegaly—Doxorubicin—muscle cancer	0.00935	0.0226	CcSEcCtD
Fludrocortisone—NR3C1—tendon—muscle cancer	0.00927	0.0172	CbGeAlD
Fludrocortisone—Impaired healing—Methotrexate—muscle cancer	0.00911	0.0221	CcSEcCtD
Fludrocortisone—NR3C1—bone marrow—muscle cancer	0.00898	0.0167	CbGeAlD
Fludrocortisone—NR3C1—vagina—muscle cancer	0.0086	0.016	CbGeAlD
Fludrocortisone—Oesophagitis—Dactinomycin—muscle cancer	0.0083	0.0201	CcSEcCtD
Fludrocortisone—NR3C1—head—muscle cancer	0.00795	0.0148	CbGeAlD
Fludrocortisone—NR3C1—testis—muscle cancer	0.00768	0.0143	CbGeAlD
Fludrocortisone—Osteoporosis—Methotrexate—muscle cancer	0.00703	0.017	CcSEcCtD
Fludrocortisone—Multiple fractures—Methotrexate—muscle cancer	0.00678	0.0164	CcSEcCtD
Fludrocortisone—Fracture—Methotrexate—muscle cancer	0.00678	0.0164	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Methotrexate—muscle cancer	0.00662	0.016	CcSEcCtD
Fludrocortisone—Hypernatraemia—Doxorubicin—muscle cancer	0.00649	0.0157	CcSEcCtD
Fludrocortisone—Oesophagitis—Etoposide—muscle cancer	0.00601	0.0146	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Etoposide—muscle cancer	0.00598	0.0145	CcSEcCtD
Fludrocortisone—Skin hyperpigmentation—Doxorubicin—muscle cancer	0.00573	0.0139	CcSEcCtD
Fludrocortisone—Optic neuritis—Doxorubicin—muscle cancer	0.00554	0.0134	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Etoposide—muscle cancer	0.00526	0.0128	CcSEcCtD
Fludrocortisone—Muscular weakness—Vincristine—muscle cancer	0.0052	0.0126	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Etoposide—muscle cancer	0.00493	0.0119	CcSEcCtD
Fludrocortisone—Petechiae—Methotrexate—muscle cancer	0.00479	0.0116	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.00468	0.0953	CbGpPWpGaD
Fludrocortisone—Dermatitis atopic—Doxorubicin—muscle cancer	0.00461	0.0112	CcSEcCtD
Fludrocortisone—Glycosuria—Doxorubicin—muscle cancer	0.00421	0.0102	CcSEcCtD
Fludrocortisone—Petechiae—Doxorubicin—muscle cancer	0.00415	0.01	CcSEcCtD
Fludrocortisone—Sweating increased—Etoposide—muscle cancer	0.00402	0.00974	CcSEcCtD
Fludrocortisone—Erythema—Dactinomycin—muscle cancer	0.00397	0.00962	CcSEcCtD
Fludrocortisone—NR3C2—Preimplantation Embryo—HMGA1—muscle cancer	0.00393	0.0801	CbGpPWpGaD
Fludrocortisone—Amenorrhoea—Doxorubicin—muscle cancer	0.00388	0.0094	CcSEcCtD
Fludrocortisone—Neoplasm—Methotrexate—muscle cancer	0.00356	0.00863	CcSEcCtD
Fludrocortisone—Ecchymosis—Methotrexate—muscle cancer	0.00356	0.00863	CcSEcCtD
Fludrocortisone—Myalgia—Dactinomycin—muscle cancer	0.00338	0.00819	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.00335	0.0682	CbGpPWpGaD
Fludrocortisone—Thrombophlebitis—Methotrexate—muscle cancer	0.0033	0.008	CcSEcCtD
Fludrocortisone—Diabetes mellitus—Methotrexate—muscle cancer	0.00329	0.00796	CcSEcCtD
Fludrocortisone—Oedema—Dactinomycin—muscle cancer	0.00324	0.00785	CcSEcCtD
Fludrocortisone—Fluid retention—Doxorubicin—muscle cancer	0.00324	0.00784	CcSEcCtD
Fludrocortisone—Infection—Dactinomycin—muscle cancer	0.00322	0.0078	CcSEcCtD
Fludrocortisone—Vertigo—Vincristine—muscle cancer	0.00319	0.00772	CcSEcCtD
Fludrocortisone—Oesophagitis—Doxorubicin—muscle cancer	0.00312	0.00755	CcSEcCtD
Fludrocortisone—Rash maculo-papular—Doxorubicin—muscle cancer	0.0031	0.00751	CcSEcCtD
Fludrocortisone—Neoplasm—Doxorubicin—muscle cancer	0.00308	0.00747	CcSEcCtD
Fludrocortisone—Ecchymosis—Doxorubicin—muscle cancer	0.00308	0.00747	CcSEcCtD
Fludrocortisone—Convulsion—Vincristine—muscle cancer	0.00307	0.00745	CcSEcCtD
Fludrocortisone—Hypertension—Vincristine—muscle cancer	0.00306	0.00742	CcSEcCtD
Fludrocortisone—Myalgia—Vincristine—muscle cancer	0.00302	0.00732	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.00301	0.0614	CbGpPWpGaD
Fludrocortisone—Anaphylactoid reaction—Methotrexate—muscle cancer	0.00295	0.00716	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00295	0.00715	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Vincristine—muscle cancer	0.0029	0.00702	CcSEcCtD
Fludrocortisone—Oedema—Vincristine—muscle cancer	0.0029	0.00702	CcSEcCtD
Fludrocortisone—Infection—Vincristine—muscle cancer	0.00288	0.00697	CcSEcCtD
Fludrocortisone—Thrombophlebitis—Doxorubicin—muscle cancer	0.00286	0.00693	CcSEcCtD
Fludrocortisone—AR—Notch-mediated HES/HEY network—MYOD1—muscle cancer	0.00285	0.0581	CbGpPWpGaD
Fludrocortisone—Diabetes mellitus—Doxorubicin—muscle cancer	0.00285	0.0069	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Vincristine—muscle cancer	0.0028	0.00678	CcSEcCtD
Fludrocortisone—Vascular purpura—Doxorubicin—muscle cancer	0.00277	0.0067	CcSEcCtD
Fludrocortisone—Cardiac failure congestive—Doxorubicin—muscle cancer	0.00273	0.00661	CcSEcCtD
Fludrocortisone—Mood swings—Methotrexate—muscle cancer	0.00271	0.00656	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00264	0.00639	CcSEcCtD
Fludrocortisone—Insomnia—Vincristine—muscle cancer	0.00262	0.00635	CcSEcCtD
Fludrocortisone—Vertigo—Etoposide—muscle cancer	0.00258	0.00626	CcSEcCtD
Fludrocortisone—Purpura—Doxorubicin—muscle cancer	0.00257	0.00622	CcSEcCtD
Fludrocortisone—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.00256	0.0062	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.00254	0.0517	CbGpPWpGaD
Fludrocortisone—Convulsion—Etoposide—muscle cancer	0.00249	0.00603	CcSEcCtD
Fludrocortisone—Hypertension—Etoposide—muscle cancer	0.00248	0.00601	CcSEcCtD
Fludrocortisone—Affect lability—Doxorubicin—muscle cancer	0.00244	0.0059	CcSEcCtD
Fludrocortisone—Pancreatitis—Methotrexate—muscle cancer	0.00242	0.00587	CcSEcCtD
Fludrocortisone—Hypersensitivity—Dactinomycin—muscle cancer	0.00239	0.00579	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Etoposide—muscle cancer	0.00235	0.00568	CcSEcCtD
Fludrocortisone—Mood swings—Doxorubicin—muscle cancer	0.00235	0.00568	CcSEcCtD
Fludrocortisone—Infection—Etoposide—muscle cancer	0.00233	0.00565	CcSEcCtD
Fludrocortisone—Asthenia—Dactinomycin—muscle cancer	0.00233	0.00563	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Etoposide—muscle cancer	0.00227	0.00549	CcSEcCtD
Fludrocortisone—Muscular weakness—Doxorubicin—muscle cancer	0.00218	0.00529	CcSEcCtD
Fludrocortisone—Abdominal distension—Doxorubicin—muscle cancer	0.00215	0.00522	CcSEcCtD
Fludrocortisone—Hypersensitivity—Vincristine—muscle cancer	0.00213	0.00517	CcSEcCtD
Fludrocortisone—Pancreatitis—Doxorubicin—muscle cancer	0.0021	0.00508	CcSEcCtD
Fludrocortisone—Asthenia—Vincristine—muscle cancer	0.00208	0.00503	CcSEcCtD
Fludrocortisone—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—muscle cancer	0.00199	0.0406	CbGpPWpGaD
Fludrocortisone—Haemoglobin—Methotrexate—muscle cancer	0.00199	0.00482	CcSEcCtD
Fludrocortisone—Haemorrhage—Methotrexate—muscle cancer	0.00198	0.00479	CcSEcCtD
Fludrocortisone—Hyperglycaemia—Doxorubicin—muscle cancer	0.00193	0.00468	CcSEcCtD
Fludrocortisone—Urticaria—Etoposide—muscle cancer	0.00186	0.00452	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	0.00184	0.0376	CbGpPWpGaD
Fludrocortisone—Headache—Vincristine—muscle cancer	0.00181	0.0044	CcSEcCtD
Fludrocortisone—Hypersensitivity—Etoposide—muscle cancer	0.00173	0.00419	CcSEcCtD
Fludrocortisone—Erythema—Methotrexate—muscle cancer	0.00172	0.00417	CcSEcCtD
Fludrocortisone—Haemoglobin—Doxorubicin—muscle cancer	0.00172	0.00417	CcSEcCtD
Fludrocortisone—Haemorrhage—Doxorubicin—muscle cancer	0.00171	0.00415	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	0.0017	0.0347	CbGpPWpGaD
Fludrocortisone—Asthenia—Etoposide—muscle cancer	0.00168	0.00408	CcSEcCtD
Fludrocortisone—Vertigo—Methotrexate—muscle cancer	0.00155	0.00375	CcSEcCtD
Fludrocortisone—Convulsion—Methotrexate—muscle cancer	0.00149	0.00361	CcSEcCtD
Fludrocortisone—Erythema—Doxorubicin—muscle cancer	0.00149	0.00361	CcSEcCtD
Fludrocortisone—Headache—Etoposide—muscle cancer	0.00147	0.00356	CcSEcCtD
Fludrocortisone—Myalgia—Methotrexate—muscle cancer	0.00147	0.00355	CcSEcCtD
Fludrocortisone—Anaphylactic shock—Methotrexate—muscle cancer	0.00141	0.0034	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	0.0014	0.0285	CbGpPWpGaD
Fludrocortisone—Infection—Methotrexate—muscle cancer	0.0014	0.00338	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Methotrexate—muscle cancer	0.00136	0.00329	CcSEcCtD
Fludrocortisone—Vertigo—Doxorubicin—muscle cancer	0.00134	0.00325	CcSEcCtD
Fludrocortisone—AR—SIDS Susceptibility Pathways—TP73—muscle cancer	0.00134	0.0273	CbGpPWpGaD
Fludrocortisone—AR—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.0013	0.0265	CbGpPWpGaD
Fludrocortisone—Convulsion—Doxorubicin—muscle cancer	0.00129	0.00313	CcSEcCtD
Fludrocortisone—Hypertension—Doxorubicin—muscle cancer	0.00129	0.00312	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00128	0.0031	CcSEcCtD
Fludrocortisone—Insomnia—Methotrexate—muscle cancer	0.00127	0.00308	CcSEcCtD
Fludrocortisone—Myalgia—Doxorubicin—muscle cancer	0.00127	0.00308	CcSEcCtD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	0.00125	0.0255	CbGpPWpGaD
Fludrocortisone—Anaphylactic shock—Doxorubicin—muscle cancer	0.00122	0.00295	CcSEcCtD
Fludrocortisone—Oedema—Doxorubicin—muscle cancer	0.00122	0.00295	CcSEcCtD
Fludrocortisone—Infection—Doxorubicin—muscle cancer	0.00121	0.00293	CcSEcCtD
Fludrocortisone—Hyperhidrosis—Doxorubicin—muscle cancer	0.00118	0.00285	CcSEcCtD
Fludrocortisone—Urticaria—Methotrexate—muscle cancer	0.00112	0.0027	CcSEcCtD
Fludrocortisone—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00111	0.00269	CcSEcCtD
Fludrocortisone—Insomnia—Doxorubicin—muscle cancer	0.0011	0.00267	CcSEcCtD
Fludrocortisone—Hypersensitivity—Methotrexate—muscle cancer	0.00104	0.00251	CcSEcCtD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—TP73—muscle cancer	0.00102	0.0207	CbGpPWpGaD
Fludrocortisone—Asthenia—Methotrexate—muscle cancer	0.00101	0.00244	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000986	0.0201	CbGpPWpGaD
Fludrocortisone—Urticaria—Doxorubicin—muscle cancer	0.000967	0.00234	CcSEcCtD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	0.000951	0.0194	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	0.000926	0.0189	CbGpPWpGaD
Fludrocortisone—NR3C2—Generic Transcription Pathway—MED12—muscle cancer	0.000909	0.0185	CbGpPWpGaD
Fludrocortisone—Hypersensitivity—Doxorubicin—muscle cancer	0.000896	0.00217	CcSEcCtD
Fludrocortisone—Headache—Methotrexate—muscle cancer	0.00088	0.00213	CcSEcCtD
Fludrocortisone—Asthenia—Doxorubicin—muscle cancer	0.000873	0.00212	CcSEcCtD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000863	0.0176	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—FOXO1—muscle cancer	0.000859	0.0175	CbGpPWpGaD
Fludrocortisone—AR—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.00078	0.0159	CbGpPWpGaD
Fludrocortisone—Headache—Doxorubicin—muscle cancer	0.000762	0.00185	CcSEcCtD
Fludrocortisone—NR3C1—Adipogenesis—HMGA1—muscle cancer	0.000726	0.0148	CbGpPWpGaD
Fludrocortisone—AR—Coregulation of Androgen receptor activity—CDKN2A—muscle cancer	0.000719	0.0146	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	0.000702	0.0143	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000631	0.0129	CbGpPWpGaD
Fludrocortisone—NR3C1—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000592	0.0121	CbGpPWpGaD
Fludrocortisone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	0.000578	0.0118	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000562	0.0115	CbGpPWpGaD
Fludrocortisone—AR—Androgen receptor signaling pathway—MDM2—muscle cancer	0.000515	0.0105	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—CDKN2A—muscle cancer	0.000488	0.00995	CbGpPWpGaD
Fludrocortisone—NR3C1—Adipogenesis—FOXO1—muscle cancer	0.000481	0.0098	CbGpPWpGaD
Fludrocortisone—NR3C2—Gene Expression—MED12—muscle cancer	0.000438	0.00891	CbGpPWpGaD
Fludrocortisone—AR—Generic Transcription Pathway—MED12—muscle cancer	0.000422	0.00859	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.000417	0.0085	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000338	0.00687	CbGpPWpGaD
Fludrocortisone—NR3C1—Generic Transcription Pathway—MED12—muscle cancer	0.00032	0.00652	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.00028	0.0057	CbGpPWpGaD
Fludrocortisone—NR3C1—AP-1 transcription factor network—TP53—muscle cancer	0.000272	0.00554	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.00027	0.00549	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000256	0.00522	CbGpPWpGaD
Fludrocortisone—AR—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.00025	0.00509	CbGpPWpGaD
Fludrocortisone—NR3C1—Glucocorticoid receptor regulatory network—TP53—muscle cancer	0.000239	0.00488	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000212	0.00433	CbGpPWpGaD
Fludrocortisone—AR—Gene Expression—MED12—muscle cancer	0.000203	0.00414	CbGpPWpGaD
Fludrocortisone—AR—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000194	0.00394	CbGpPWpGaD
Fludrocortisone—NR3C1—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000189	0.00386	CbGpPWpGaD
Fludrocortisone—AR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.00016	0.00327	CbGpPWpGaD
Fludrocortisone—NR3C1—Gene Expression—MED12—muscle cancer	0.000154	0.00314	CbGpPWpGaD
